array:23 ["pii" => "S225380892100121X" "issn" => "22538089" "doi" => "10.1016/j.remnie.2021.07.001" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "1321" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Esp Med Nucl Imagen Mol. 2021;40:339-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X21001396" "issn" => "2253654X" "doi" => "10.1016/j.remn.2021.07.001" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "1321" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Esp Med Nucl Imagen Mol. 2021;40:339-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Carta al Director" "titulo" => "Vacunación SARS-CoV-2 y tratamiento con radiofármacos: documento del Grupo de Trabajo de Endocrinología de la SEMNIM" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "339" "paginaFinal" => "340" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "SARS-Cov-2 vaccination and metabolic radionuclide therapy: document of the SEMNIM Endocrinology Working Group" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Negre Busó, A. Rodríguez Gasen, È. Torrent Llongarriu, M. Estorch Cabrera" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Negre Busó" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Rodríguez Gasen" ] 2 => array:2 [ "nombre" => "È." "apellidos" => "Torrent Llongarriu" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Estorch Cabrera" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S225380892100121X" "doi" => "10.1016/j.remnie.2021.07.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225380892100121X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X21001396?idApp=UINPBA00004N" "url" => "/2253654X/0000004000000005/v1_202108200653/S2253654X21001396/v1_202108200653/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2253808921000501" "issn" => "22538089" "doi" => "10.1016/j.remnie.2020.11.002" "estado" => "S300" "fechaPublicacion" => "2021-09-01" "aid" => "1249" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2021;40:337-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Interesting images" "titulo" => "A rare case of diffuse and bilateral pulmonary uptake in 18F-FDG PET/CT scan" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "337" "paginaFinal" => "338" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Un caso raro de captación pulmonar difusa y bilateral en 18F-FDG PET/TC" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 730 "Ancho" => 1750 "Tamanyo" => 126743 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "[18F] FDG-PET / CT. A) MIP image (maximum intensity projection) of FDG-PET showing diffuse pulmonary hypermetabolism of decreasing intensity to the bases and homogeneous uptake in axial and extra axial bonerrow. No other significant metabolic findings suggestive of malignancy. B, C and D) Axial, coronal and sagittal plane of fusioned [18F]FDG-PET/CT showing extensive areas of bilateral ground glass with predominantly apical radiopharmaceutical avidity (SUVmax 10.8). E, F and G) Axial, coronal and sagittal CT sections: extensive areas of ground glass and consolidations." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Oliván-Sasot, R. Sánchez-Vañó, P. Calvillo-Batllés, J. Belda Ramirez, P. Bello-Arques" "autores" => array:5 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Oliván-Sasot" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Sánchez-Vañó" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Calvillo-Batllés" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Belda Ramirez" ] 4 => array:2 [ "nombre" => "P." "apellidos" => "Bello-Arques" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X20302122" "doi" => "10.1016/j.remn.2020.11.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X20302122?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808921000501?idApp=UINPBA00004N" "url" => "/22538089/0000004000000005/v1_202108210518/S2253808921000501/v1_202108210518/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "SARS-CoV-2 vaccination and metabolic radionuclide therapy: Document of the SEMNIM Endocrinology Working Group" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "339" "paginaFinal" => "340" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Montserrat Negre Busó, Alba Rodríguez Gasen, Èlia Torrent Llongarriu, Montserrat Estorch Cabrera" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Montserrat" "apellidos" => "Negre Busó" "email" => array:1 [ 0 => "montserrat.negre.idi@gencat.cat" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Alba" "apellidos" => "Rodríguez Gasen" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 2 => array:3 [ "nombre" => "Èlia" "apellidos" => "Torrent Llongarriu" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Montserrat" "apellidos" => "Estorch Cabrera" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Medicina Nuclear-IDI, Hospital Universitari de Girona Dr. Josep Trueta, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Medicina Nuclear, Hospital Universitari de Bellvitge, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Grupo de trabajo de Endocrinología de la SEMNIM, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Avda de França s/n, 17007, Girona, Catalunya, Spain." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vacunación SARS-CoV-2 y tratamiento con radiofármacos: documento del Grupo de Trabajo de Endocrinología de la SEMNIM" ] ] "textoCompleto" => "At the end of 2019 the COVID-19 pandemic began, and we have remained in its grip since then.Following the advice of different professional societies and health care authorities Nuclear Medicine Departments throughout the work adapted to the new circumstance, restructuring the planning of not only diagnostic techniques but also therapeutic procedures with radiopharmaceuticals<a class="elsevierStyleCrossRef" href="#bib0005">1</a>. During the first months of the pandemic health care activity related to conventional nuclear medicine drastically reduced, with this reduction being much more moderate in metabolic therapy procedures and relatively low in positron emission tomography/computerized tomography studies<a class="elsevierStyleCrossRef" href="#bib0010">2</a>. Later on, little by little we adapted to the new normality, and the usual numbers of diagnostic and therapeutic studies were reestablished.Nonetheless, the arrival of the vaccines against COVID-19 has led to a new paradigm. According to data obtained from the Ministry of Health at the time of writing this article, in Spain 39.9 million doses had been administered, with more than 24 million persons having received one dose (52.8%) and more than 16 million having completed the full vaccination schedule (35.4% of the population).In our metabolic therapy consultations we increasingly come across doubts of the patients regarding possible interactions between the vaccine and the treatment administered. On behalf of the SEMNIM Endocrinology Working Group we wish to give some recommendations on how metabolic therapy departments should act.In Spain 4 types of vaccine against SARS-CoV-2 are currently approved: <ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">-Biontech/Pfizer(Comirnaty): mRNA which codifies the enveloped Spike (S) protein in lipid nanoparticles.</li><li class="elsevierStyleListItem" id="lsti0010">-Moderna: mRNA which codifies the enveloped Spike (S) protein in lipid particles.</li><li class="elsevierStyleListItem" id="lsti0015">-Astra-Zeneca/Oxford (Vaxzevria): replication deficient recombinant chimpanzee adenovirus expressing the Spike (S) protein.</li><li class="elsevierStyleListItem" id="lsti0020">-Janssen: replication deficient recombinant human adenovirus expressing the Spike (S) protein.</li><li class="elsevierStyleListItem" id="lsti0025">-According to the Summary of Product Characteristics of the four vaccines (3-available at <a href="https://cima.aemps.es/cima/publico/home.html">https://cima.aemps.es/cima/publico/home.html</a>), there are no studies of interactions with other medications and other concomitant vaccines. In the search for information on interactions currently reported with the administration of the vaccines (4-<a href="https://www.drugs.com">https://www.drugs.com</a>), 264 pharmacological interactions have been described (263 moderate and one mild), being the same for each type of vaccine. These interactions include the use of [177Lu]Lu-DOTA-TATE and [131I]MIBG, with treatment with [131I]NaI not being found among the interactions.</li></ul>According to different documents available from the National Health Service of the United Kingdom and the Centers for Disease Control and Prevention of the United States, the reason why these two types of therapy with radiopharmaceuticals are included is the possibility of immunosuppression with these treatments. Although the administration of vaccines with inactivated virus or a non-infectious vaccine is generally safe in immunosuppressed patients, this condition may carry less immunological response (suboptimal response) to the vaccine. To minimize this possibility it is recommended to space out the treatment a minimum of two weeks (Immunization Against Infectious Disease – “The Green Book”. Chapter 6: <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap</a>; Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States: <a href="https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Coadministration">https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html#Coadministration</a>; General Best Practice Guidelines for Immunization: Altered Immunocompetence: <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf</a>).On the other hand, treatment with radioiodine for thyroid disease (hyperthyroidism or differentiated thyroid cancer) does not seem to interfere with the immunological response of the vaccine.The American Thyroid Association (<a href="https://www.thyroid.org/covid-19">https://www.thyroid.org/covid-19</a>), the European Thyroid Association (<a href="https://www.eurothyroid.com/news/covid-19-vaccination-thyroid-disease.html">https://www.eurothyroid.com/news/covid-19-vaccination-thyroid-disease.html</a>) and the European Society of Endocrinology (<a href="https://www.ese-hormones.org/about-us/our-communities/clinicians/covid-19-and-endocrine-disease">https://www.ese-hormones.org/about-us/our-communities/clinicians/covid-19-and-endocrine-disease</a>), recommend the administration of the vaccine to all patients with thyroid diseases such as autoimmune disease (Hashimoto thyroiditis, Graves-Basedow disease) or thyroid cancer, if they are clinically stable. The recommendations specifically advise against the delay of treatment with radiopharmaceuticals, although treatment planning should be discussed with the attending physician.In relation to the treatment of differentiated thyroid cancer with radioiodine, a thyroid-stimulating hormone (TSH) value >30 IU/mL is required for being effective. This rate can be achieved by stimulation with recombinant TSH (Thyrogen®) or by withdrawal of hormone replacement medication (levothyroxine) during 4 weeks, producing transitory hypothyroidism. At present, there are no publications in the scientific literature regarding interactions between Thyrogen® and the SARS-CoV-2 vaccine or between the induction of hypothyroidism and the effectiveness of the vaccine. Neither has there been any update on the precautions of adverse effects in the official Summary of Product Characteristics of the drug published by the Spanish Agency of Medication and Health Care Products. Moreover, professionals from Sanofi España reported no interactions between Thyrogen® and the vaccine, thereby recommending vaccination according to the official vaccination calendar of each region.Other interactions and recommendations:An autoimmune/inflammatory syndrome induced by adjuvants of the vaccines (known as ASIA) was described a decade ago in relation to clinical manifestations derived from the potentiation of the immune system provoked by some vaccines and mainly associated with the human papilloma virus, influenza and hepatitis B<a class="elsevierStyleCrossRef" href="#bib0015">3</a>. The development of Graves disease is among the spectrum of possible clinical presentations<a class="elsevierStyleCrossRef" href="#bib0020">4</a>.Recently, in May 2021, the journal “Thyroid” (official publication of the American Thyroid Association), described 2 cases of Graves disease after the administration of the Pfizer-BioNTech vaccine. In these two cases, the clinical manifestations of hyperthyroidism occurred 2–3 days after administration of the vaccine. Therefore, it is recommended to include the history of vaccination against SARS-CoV-2 when considering treatment with radioiodine in patients referred for hyperthyroidism<a class="elsevierStyleCrossRef" href="#bib0025">5</a>.To conclude, it is recommended to evaluate each individual case with respect to the treatment to be performed and the type of radiopharmaceutical, considering possible adverse effects and the dose to administer. If there is the possibility of the treatment causing immunosuppressive effects, which could induce suboptimal response to vaccination, it is recommended to space the treatment with radiopharmaceuticals by at least two weeks after the administration of the vaccine." "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Negre Busó M, Rodríguez Gasen A, Torrent Llongarriu È, Estorch Cabrera M. Vacunación SARS-CoV-2 y tratamiento con radiofármacos: documento del Grupo de Trabajo de Endocrinología de la SEMNIM. Rev Esp Med Nucl Imagen Mol. 2021;40:339–340." ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Medicina Nuclear en la pandemia por Covid-19" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Castell-Conesa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2020.05.001" "Revista" => array:7 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2020" "volumen" => "39" "numero" => "3" "paginaInicial" => "138" "paginaFinal" => "139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32451165" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Annunziata" 1 => "M. Bauckneht" 2 => "D. Albano" 3 => "G. Argiroffi" 4 => "D. Calabro" 5 => "E. Abenavoli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-020-04874-z" "Revista" => array:7 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2020" "volumen" => "47" "numero" => "9" "paginaInicial" => "2090" "paginaFinal" => "2099" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32462398" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Watad" 1 => "P. David" 2 => "S. Brown" 3 => "Y. Shoenfeld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Front Endocrinol (Lausanne)" "fecha" => "2017" "volumen" => "7" "paginaInicial" => "150" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ASIA syndrome and endocrine autoimmune disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N.L. Bragazzy" 1 => "A. Hejly" 2 => "A. Watad" 3 => "M. Adawi" 4 => "H. mital" 5 => "Y. Shoenfeld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Best Pract Res Clin Endocrinol Metab" "fecha" => "2020" "volumen" => "34" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Vera-Lastra O, Ordinola Navarro A, Cruz Dominguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. Ahead of print. <a target="_blank" href="https://doi.org/10.1089/thy.2021.0142">https://doi.org/10.1089/thy.2021.0142</a>." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000004000000005/v1_202108210518/S225380892100121X/v1_202108210518/en/main.assets" "Apartado" => array:4 [ "identificador" => "22541" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letter to the editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000004000000005/v1_202108210518/S225380892100121X/v1_202108210518/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225380892100121X?idApp=UINPBA00004N"]

ISSN: 2253-8089

The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles. The works may be submitted in Spanish or English and are subjected to a peer review process. In 2009, it became the leading Spanish journal in the field of Medical Imaging on having an Impact Factor , awarded by the Journal Citation Reports.

See more Open Access Option

Indexed in:

Science Citation Index Expander, Medline, IME, Bibliomed, EMBASE/Excerpta Medica, Healthstar, Cancerlit, Toxine, Inside Conferences, Scopus

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

1.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.208

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.273

View more metrics

Journal Information

Previous article | Next article

Lee este artículo en Español

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

Además del acceso temporal al artículo, este le será enviado por correo electrónico.

Atención al cliente

Phone

Llamadas desde España

932 415 960

Llamadas desde el extranjero

+34 932 415 960

Horario de 9 a 18h. excepto los meses de julio y agosto que será de 9 a 15h.

Publish in

Revista Española de Medicina Nuclear e Imagen Molecular

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Free access articles

Imaging of desmoplastic small round-cell tumor on

Rev Esp Med Nucl Imagen Mol. 2024;43:

Assessment of incidental cardiac uptake in bone...

Rev Esp Med Nucl Imagen Mol. 2024;43:

Diagnostic performance of a novel deep learning attenuation...

Rev Esp Med Nucl Imagen Mol. 2024;43:23-30

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter